Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma

doi:10.1016/0090-8258(92)90075-T

Gynecologic Oncology

Volume 47, Issue 1, October 1992, Pages 53-57

https://doi.org/10.1016/0090-8258(92)90075-T Get rights and content

Abstract

The slides of all patients with ovarian cystadenocarcinoma treated at the University of Kentucky Medical Center from 1966–1990 were reviewed. Fifty-four serous tumors and 42 mucinous neoplasms were identified for further study. Benign epithelium adjacent to an area of borderline or malignant epithelium was observed in 74 tumors (79%) and a site of epithelial transition was noted in 38 cases (40%). The presence of associated benign epithelium was more common in borderline or well-differentiated lesions and in patients with early-stage disease. These findings are consistent with epidemiologic and molecular genetic data and suggest that certain benign serous or mucinous ovarian tumors have the potential for malignant transformation. Removal of these tumors, particularly in postmenopausal women, should result in a subsequent reduction in the frequency of ovarian cancer.

References (19)

T.H. Bourne et al.
Ultrasound screening for familial ovarian cancer
Gynecol. Oncol.
(1991)
F. Stenback
Benign, borderline and malignant serous cystadenomas of the ovary
Pathol. Res. Pract.
(1981)
S.C. Plaxe et al.
Ovarian intraepithelial neoplasia demonstrated in patients with Stage I ovarian carcinoma
Gynecol. Oncol.
(1990)
D.D. Snider et al.
Evaluation of surgical staging in Stage I low malignant potential ovarian tumor
Gynecol. Oncol.
(1991)
F.L. Tyson et al.
Expression, amplification of the HER-2/NEU (C-erb B-2) proto-oncogene in epithelial ovarian tumors and cell lines
Am. J. Obstet. Gynecol.
(1991)
C. Boring et al.
Cancer Statistics 1992
Ca Bull. Cancer Prog.
(1992)
H. Gallion et al.
Adjuvant oral alkylating agent chemotherapy in patients with Stage I epithelial ovarian cancer
Cancer
(1989)
R.C. Young et al.
Adjuvant therapy in Stage I and Stage II epithelial ovarian cancer
N. Engl. J. Med.
(1990)
B.S. Hulka
Cancer screening: Degrees of proof and practical application
Cancer
(1989)

There are more references available in the full text version of this article.

Cited by (162)

Adnexal masses
2023, DiSaia and Creasman Clinical Gynecologic Oncology
The adnexae consist of the fallopian tubes, broad ligament, ovaries, and structures within the broad ligament that are formed from embryologic rests. Detection of pelvic abnormalities is more frequent in women of reproductive age because these patients have serial examinations as part of periodic screening for cancer (i.e., Pap testing) and contraceptive counseling. Management of an adnexal mass is complex because of the scope of the disorders it encompasses and the numerous therapies that may be appropriate. The risk of malignancy and the fundamental concept that early diagnosis and treatment in cancer are related to reduced mortality and morbidity propel the system. An adnexal mass often involves ovarian substance because of the propensity of the ovary for neoplasia. Fewer neoplasms occur in the fallopian tube, although that structure may commonly be involved in an inflammatory process that manifests as an adnexal mass. It is estimated that 5% to 10% of women in the United States will undergo a surgical procedure for a suspected ovarian neoplasm during their lifetime, and 13% to 21% of these women will be found to have an ovarian malignant neoplasm. The overwhelming majority of adnexal masses are benign, and it is important to determine preoperatively whether a patient is at high risk for ovarian malignant disease to minimize the number of operative procedures performed for self-limited processes.
Progression of Cystadenoma to Mucinous Borderline Ovarian Tumor in Young Females: Case Series and Literature Review
2022, Journal of Pediatric and Adolescent Gynecology
To study the progression of benign ovarian lesions to mucinous borderline ovarian tumors (mBOTs); analyze the clinicopathologic features, diagnosis, and management of mBOTs in pediatric and adolescent girls; and provide a review of the literature on mBOTs in this population.
Retrospective chart review of female adolescents younger than 18 years diagnosed with mBOTs between July 2017 and February 2021.
Yale New Haven Hospital, New Haven, Connecticut; and Yale New Haven Health Bridgeport Hospital, Bridgeport, Connecticut.
Three female patients diagnosed with mBOTs between ages 12 and 17 years.
None.
Clinical presentation, preoperative characteristics, surgical technique, histology, tumor stage, treatment, progression, outcome, and rate of recurrence.
Three adolescent patients were identified to have mBOTs. All three patients presented with a chief complaint of abdominal pain. One of the 3 patients was premenarchal at presentation. Two of the 3 patients were initially diagnosed with a mucinous cystadenoma and had recurrences of an ovarian cyst in the same ovary within 5 and 17 months, respectively. Pathology of the recurrent cyst was consistent with mBOT. Two of the 3 patients initially underwent cystectomy, and all ultimately had a unilateral salpingo-oophorectomy. Subsequent surveillance over 2 to 4 years found no evidence of disease recurrence.
mBOTs are rare in the pediatric and adolescent population and could arise from benign ovarian tumors.
High grade serous intraepithelial carcinoma arising in a benign ovarian serous cyst – a bridge too far?
2018, Pathology
Adnexal masses
2018, Clinical Gynecologic Oncology
Ultrasound-Guided Aspiration With and Without Ethanol Sclerotherapy in the Management of Simple Adnexal Cysts: A Single-Center Experience
2016, Journal of Minimally Invasive Gynecology
To compare the efficacy of ultrasound-guided aspiration versus aspiration with ethanol sclerotherapy in the management of simple adnexal cysts measuring 3 to 10 cm, and to explore the risk factors for recurrence associated with each approach.
A prospective follow-up of patients after cyst aspiration with and without ethanol sclerotherapy in simple adnexal cysts in a single-center trial (Canadian Task Force classification II-1).
Bellvitge Teaching Hospital, Barcelona, Spain.
Cyst aspiration and ethanol sclerotherapy were performed in 66 and 75 patients, respectively, between 2002 and 2014. Women enrolled before March 2009 underwent simple aspiration (group 1), and those enrolled after March 2009 underwent ethanol sclerotherapy (group 2).
Ultrasound-guided fine-needle aspiration with and without ethanol sclerotherapy.
Potential risk factors for recurrence—age, menopausal status, symptoms, cyst diameter, laterality, aspirated volume, simple US-guided aspiration or alcohol sclerotherapy, and complications—were analyzed by logistic regression. The recurrence rates were analyzed by the Kaplan–Meier and Mantel–Haenszel methods. The overall recurrence rates were 72.7% (48 of 66) in group 1 and 22.7% (17 of 75) in group 2 (p < .0001). Risk factors significantly associated with recurrence were simple aspiration without ethanol sclerotherapy (odds ratio [OR], 19.7; 95% confidence interval [CI], 6.756–57.714), postmenopausal status (OR, 9.3; 95% CI, 1.720–50.956), and cyst size (OR, 1.04; 95% CI, 1.005–1.093).
Based on the lower recurrence rate, ethanol sclerotherapy was more efficacious than simple aspiration in the management of simple adnexal cysts measuring <10 cm.
Ultrasound follow up of an adnexal mass has the potential to save lives
2015, American Journal of Obstetrics and Gynecology
Ovarian cancer is among the most dreaded cancers since it is often found at a late stage where the opportunity for extended survival is poor. Ultrasound has been utilized in several ovarian cancer screening trials in asymptomatic women in order to detect ovarian cancer at early stages where survival rates are high. Efforts to improve screening for ovarian cancer are ongoing. While ovarian cancer screening in asymptomatic women is not recommended for clinical application currently, the care of women with adnexal masses found by ultrasound in clinical practice can benefit from close evaluation of the evidence obtained from large prospective ovarian cancer screening trials and by relating this evidence to recent advances in the understanding of different types of ovarian cancer. Post-menopausal women who have an adnexal mass discovered by ultrasound have a much higher risk of developing ovarian cancer than women with normal ultrasound. The preponderance of reported evidence indicates that ultrasound monitoring of an adnexal mass is safe, cost effective and can achieve an improved positive predictive value in detecting ovarian cancer when ovarian abnormalities resolve during surveillance. Proposals to arbitrarily discontinue ultrasound monitoring can negatively impact patient care and generate medical-legal actions, especially because there is no evidence to support safe discontinuation. In this review, we outline a rationale for continuing ultrasound surveillance of ovarian abnormalities.

View all citing articles on Scopus

^☆: Presented at the 23rd Annual Meeting of the Society of Gynecologic Oncologists, San Antonio, TX, March 15–18, 1992.

¹: American Cancer Society clinical career development awardee.

²: American Cancer Society professor of clinical oncology.

View full text

SGO articleTransition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma☆

Abstract

Gynecol. Oncol.

Pathol. Res. Pract.

Gynecol. Oncol.

Gynecol. Oncol.

Am. J. Obstet. Gynecol.

Cancer Statistics 1992

Ca Bull. Cancer Prog.

Adjuvant oral alkylating agent chemotherapy in patients with Stage I epithelial ovarian cancer

Cancer

Adjuvant therapy in Stage I and Stage II epithelial ovarian cancer

N. Engl. J. Med.

Cancer screening: Degrees of proof and practical application

Cancer

SGO article
Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma☆